PF-AtlasClinical Trials › NCT06573164

Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis

Bacillus clausii tablets(Qipian®) · Not specified

Registry ID
NCT06573164
Phase
Not specified
Status
Completed
Drug / intervention
Bacillus clausii tablets(Qipian®)
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Start
2024-01-01
Enrollment
60
Locations
1

About this trial

Allergic rhinitis and asthma are common respiratory diseases. Qipian® is a Chinese medicine made from three types of bacteria, used to treat these conditions. This study will retrospectively analyze the effects of adding Qipian® to the regular treatment for patients with allergic rhinitis, with or without asthma. Patients meeting the Allergic Rhinitis and its Impact on Asthma(ARIA) and Global Initiative for Asthma(GINA) diagnostic criteria were divided into two groups: one receiving standard drug treatment, and the other receiving standard treatment plus Qipian®. The study will compare clinical symptoms and relevant blood markers before and after treatment to see if adding Qipian® leads to better outcomes than the standard treatment alone.This study aims to determine how Qipian® benefits patients with rhinitis and asthma and its effect on related serum indicators, helping to explore its role in allergic respiratory diseases.

View NCT06573164 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT06573164 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.